Airway microbiota across age and disease spectrum in cystic fibrosis

Edith T. Zemanick*, Brandie D. Wagner, Charles E. Robertson, Richard C. Ahrens, James F. Chmiel, John P. Clancy, Ronald L. Gibson, William T. Harris, Geoffrey Kurland, Theresa A. Laguna, Susanna A. McColley, Karen McCoy, George Retsch-Bogart, Kurtis T. Sobush, Pamela L. Zeitlin, Mark J. Stevens, Frank J. Accurso, Scott D. Sagel, J. Kirk Harris

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

177 Scopus citations

Abstract

Our objectives were to characterise the microbiota in cystic fibrosis (CF) bronchoalveolar lavage fluid (BALF), and determine its relationship to inflammation and disease status. BALF from paediatric and adult CF patients and paediatric disease controls undergoing clinically indicated bronchoscopy was analysed for total bacterial load and for microbiota by 16S rDNA sequencing. We examined 191 BALF samples (146 CF and 45 disease controls) from 13 CF centres. In CF patients aged <2 years, nontraditional taxa (e.g. Streptococcus, Prevotella and Veillonella) constituted ∼50% of the microbiota, whereas in CF patients aged ?6 years, traditional CF taxa (e.g. Pseudomonas, Staphylococcus and Stenotrophomonas) predominated. Sequencing detected a dominant taxon not traditionally associated with CF (e.g. Streptococcus or Prevotella) in 20% of CF BALF and identified bacteria in 24% of culturenegative BALF. Microbial diversity and relative abundance of Streptococcus, Prevotella and Veillonella were inversely associated with airway inflammation. Microbiota communities were distinct in CF compared with disease controls, but did not differ based on pulmonary exacerbation status in CF. The CF microbiota detected in BALF differs with age. In CF patients aged <2 years, Streptococcus predominates, whereas classic CF pathogens predominate in most older children and adults.

Original languageEnglish (US)
Article number1700832
JournalEuropean Respiratory Journal
Volume50
Issue number5
DOIs
StatePublished - Nov 1 2017

Funding

Support statement: This study was supported by the Cystic Fibrosis Foundation grant ZEMANI11A0, National Institutes of Health grant K23HL114883 and NIH/NCATS Colorado CTSA grant UL1 TR001082. Contents are the authors’ sole responsibility and do not necessarily represent official National Institutes of Health views. Funding information for this article has been deposited with the Crossref Funder Registry.

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Airway microbiota across age and disease spectrum in cystic fibrosis'. Together they form a unique fingerprint.

Cite this